Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05488678 · ClinicalTrials.gov registry record · Phase 1
Ceftibuten/VNRX-7145 in Participants With Varying Degrees of Renal Function
A Phase 1 study, sponsored by Basilea Pharmaceutica.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT05488678 is a Phase 1 study that has completed, run by Basilea Pharmaceutica. The registered enrollment target is 32 participants.
The verdict
NCT05488678, a Phase 1 study, has completed, sponsored by Basilea Pharmaceutica.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This is an open-label, multicenter, parallel-group study in participants with normal renal function, mild, moderate, or severe renal impairment, or end stage renal disease (ESRD) undergoing standard intermittent dialysis. The pharmacokinetics (PK) of the inactive prodrug VNRX-7145, its active parent drug VNRX-5236, and ceftibuten will be evaluated after a single oral dose of ceftibuten/VNRX-7145.
Interventions
- DRUG Ceftibuten
- DRUG VNRX-7145
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2022-10-12 |
| Est. Completion | 2023-11-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05488678
The ClinicalTrials.gov registry entry for NCT05488678 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Basilea Pharmaceutica, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ceftibuten is the first listed.
NCT05488678 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05488678 about?
NCT05488678 is a clinical study titled "Ceftibuten/VNRX-7145 in Participants With Varying Degrees of Renal Function". This is an open-label, multicenter, parallel-group study in participants with normal renal function, mild, moderate, or severe renal impairment, or end stage renal disease (ESRD) undergoing standard intermittent dialysis. The pharmacokinetics (PK) of the inactive prodrug VNRX-7145, its active parent...
What is the current status of trial NCT05488678?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2022-10-12. Estimated completion is 2023-11-23.
What interventions are being tested in trial NCT05488678?
The interventions under investigation include: Ceftibuten (DRUG), VNRX-7145 (DRUG).
Who is sponsoring clinical trial NCT05488678?
This trial is sponsored by Basilea Pharmaceutica, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.